Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biotechnology firm Archemix has said that it will receive a milestone payment from its collaborator Ophthotech.
Subscribe to our email newsletter
The milestone payment has been triggered by Ophthotech’s enrollment of the first volunteer in a Phase I study of E10030, an anti-platelet derived growth factor aptamer which is being developed for age related macular degeneration.
Errol De Souza, president and CEO of Archemix, said: “Ophthotech is our second collaborator to advance an aptamer into human clinical trials thus far in 2008 and, overall, E10030 becomes the fourth aptamer being tested in humans by our collaborators.”